Type 2 Diabetes

NEW ORLEANS — Tirzepatide, a novel glucose-lowering therapy, reduced urinary albumin secretion and slowed kidney function decline for adults with type 2 diabetes and high cardiovascular risk, according to data from the SURPASS-4 trial.

The American Diabetes Association announced updates to its 2022 Standards of Medical Care in Diabetes to reflect new data on cardiovascular outcomes with diabetes and kidney disease and use of SGLT2 inhibitors.

Aerobic training and daily intake of pure pomegranate juice may prevent increased liver enzymes and insulin resistance in adult men, according to findings from an Iranian study published in BMC Nutrition.

People with type 2 diabetes who achieved recommended targets for HbA1c, systolic blood pressure, LDL cholesterol and BMI had increased life expectancy, although the size of increase differed among the biomarkers, concluded recent research.

Fewer than one in 10 adults with type 2 diabetes in the U.S. use SGLT2 inhibitors or GLP-1 receptor agonists, and only SGLT2 inhibitors have seen an increase in use over the last decade, according to study findings.

Nationwide, there is significantly increased interest and focus on addressing racial and ethnic health disparities.

Eldecalcitol, a vitamin D analog, is not associated with a reduced incidence of type 2 diabetes among adults with prediabetes, though it may have a beneficial effect in those with lower insulin secretion, according to study data.

For patients with type 2 diabetes, first-line SGLT2 inhibitors might be better than metformin when it comes to their cardiovascular health, according to results of a population-based cohort study.

Compared with conventional treatment, bariatric surgery was superior in achieving remission of prediabetes and type 2 diabetes and reducing cardiometabolic risks for patients with obesity, researchers reported in Obesity Medicine.

COVID-19 survivors face a significantly higher risk than control patients for developing conditions affecting major system of the body, according to a study of nearly 2 million patients.